Form 10-K
TEVA PHARMACEUTICAL INDUSTRIES LTD filed this Form 10-K on 02/12/2018
Document Outline
Entire Document (15211.6 KB)
Subdocument 1 - 10-K - FORM 10-K
Page 1 - UNITED STATES
Page 2 - TABLE OF CONTENTS
Page 3 - INTRODUCTION AND USE OF CERTAIN TERMS
Page 4 - PART I
Page 5 - Changes in Senior Management
Page 6 - Transactions
Page 7 - OTC
Page 8 - APIs
Page 9 - Rest of the World Markets
Page 10 - Central Nervous System Medicines
Page 11 - AUSTEDO
Page 12 - Laquinimod
Page 13 - Fasinumab
Page 14 - TV-45070
Page 15 - QVAR
Page 16 - CINQAIR /CINQAERO
Page 17 - Respiratory Pipeline
Page 18 - BENDEKA and TREANDA
Page 19 - Oncology Pipeline
Page 20 - Generics
Page 21 - Operations
Page 22 - Raw Materials for Pharmaceutical Production
Page 23 - Quality
Page 24 - Specialty Medicines Competition
Page 25 - N/A
Page 26 - The Patient Protection and Affordable Care Act and Certain Government Programs
Page 27 - Europe
Page 28 - Rest of World
Page 29 - Miscellaneous Regulatory Matters
Page 30 - Available Information
Page 31 - Sales of our generic products may be adversely affected by the continuing consolidation of our custo
Page 32 - Our revenues and profits from generic products may, and often do, decline as a result of competition
Page 33 - If pharmaceutical companies are successful in limiting the use of generics through their legislative
Page 34 - Investigations of the calculation of wholesale prices may adversely affect our business.
Page 35 - Investments in our pipeline of specialty and other products may not achieve expected results.
Page 36 - Our specialty pharmaceuticals business faces intense competition from companies that have greater re
Page 37 - Risks related to our substantially increased indebtedness
Page 38 - We may need to raise additional funds in the future, which may not be available on acceptable terms
Page 39 - Additional risks related to our business and operations
Page 40 - Uncertainties related to, and failure to achieve, the potential benefits and success of our new seni
Page 41 - The expected review of our R D programs may harm our pipeline of future products.
Page 42 - Sanctions and other trade control laws create the potential for significant liabilities, penalties a
Page 43 - Manufacturing or quality control problems may damage our reputation for quality production, demand c
Page 44 - Significant disruptions of our information technology systems or breaches of our data security could
Page 45 - We have significant operations globally, including in countries that may be adversely affected by po
Page 46 - We may not be able to find or successfully bid for suitable acquisition targets or licensing opportu
Page 47 - Compliance, regulatory and litigation risks
Page 48 - Governmental investigations into sales and marketing practices, particularly for our specialty pharm
Page 49 - We may be susceptible to significant product liability claims that are not covered by insurance.
Page 50 - Our failure to comply with applicable environmental laws and regulations worldwide could adversely i
Page 51 - Our long-lived assets may continue to lead to significant impairments in the future.
Page 52 - Equity ownership risks
Page 53 - Our ADSs and ordinary shares are traded on different markets and this may result in price variations
Page 54 - N/A
Page 55 - PART II
Page 56 - Holders
Page 57 - Performance Graph
Page 58 - Operating Data
Page 59 - Business Overview
Page 60 - Highlights
Page 61 - Changes in Senior Management
Page 62 - Fremanezumab
Page 63 - Segment Information
Page 64 - United States Generic Medicines Revenues
Page 65 - Products
Page 66 - N/A
Page 67 - Europe Generic Medicines Revenues
Page 68 - Comparison of 2016 to 2015
Page 69 - Comparison of 2016 to 2015.
Page 70 - Specialty Medicines Revenues
Page 71 - COPAXONE
Page 72 - Comparison of 2016 to 2015.
Page 73 - Comparison of 2016 to 2015.
Page 74 - Comparison of 2016 to 2015
Page 75 - Gross Profit
Page 76 - Comparison of 2016 to 2015.
Page 77 - Comparison of 2016 to 2015.
Page 78 - Comparison of 2016 to 2015.
Page 79 - Net Income (Loss)
Page 80 - Impact of Currency Fluctuations on Results of Operations
Page 81 - 2017 Debt Balance and Movements
Page 82 - 2016 Debt Movements
Page 83 - Total Equity
Page 84 - Dividends
Page 85 - Supplemental Non-GAAP Income Data
Page 86 - N/A
Page 87 - N/A
Page 88 - N/A
Page 89 - Non-GAAP Effective Tax Rate
Page 90 - Trend Information
Page 91 - Off-Balance Sheet Arrangements
Page 92 - Customer Volume Rebates.
Page 93 - Prompt Pay Discounts.
Page 94 - Income Taxes
Page 95 - U.S. Tax Cuts and Jobs Act
Page 96 - Inventories
Page 97 - Generics reporting units
Page 98 - N/A
Page 99 - Other reporting units within generics
Page 100 - Specialty reporting unit
Page 101 - Contingent consideration
Page 102 - Restructuring Costs
Page 103 - General
Page 104 - Outstanding Foreign Exchange Hedging Transactions
Page 105 - Foreign Subsidiaries Net Assets
Page 106 - N/A
Page 107 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 108 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Page 109 - Definition and Limitations of Internal Control over Financial Reporting
Page 110 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 111 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 112 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 113 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 114 - TEVA PHARMACEUTICAL INDUSTRIES
Page 115 - TEVA PHARMACEUTICAL INDUSTRIES
Page 116 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 117 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 118 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 119 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 120 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 121 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 122 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 123 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 124 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 125 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 126 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 127 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 128 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 129 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 130 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 131 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 132 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 133 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 134 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 135 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 136 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 137 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 138 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 139 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 140 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 141 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 142 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 143 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 144 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 145 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 146 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 147 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 148 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 149 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 150 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 151 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 152 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 153 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 154 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 155 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 156 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 157 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 158 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 159 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 160 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 161 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 162 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 163 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 164 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 165 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 166 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 167 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 168 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 169 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 170 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 171 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 172 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 173 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 174 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 175 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 176 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 177 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 178 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 179 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 180 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 181 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 182 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 183 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 184 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 185 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 186 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 187 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 188 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 189 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 190 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 191 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 192 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 193 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 194 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 195 - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Page 196 - Disclosure Controls and Procedures
Page 197 - PART III
Page 198 - N/A
Page 199 - N/A
Page 200 - N/A
Page 201 - N/A
Page 202 - Executive Officers
Page 203 - N/A
Page 204 - N/A
Page 205 - Family Relationships
Page 206 - Code of Business Conduct
Page 207 - I. Executive Summary
Page 208 - Components of Compensation and Target Pay Mix
Page 209 - Corporate Governance Practices
Page 210 - Compensation-Related Requirements of the Israeli Companies Law
Page 211 - Compensation Proposal Results and Shareholder Feedback
Page 212 - III. Compensation Determination Process
Page 213 - Key Participants
Page 214 - Role of Independent Compensation Consultant
Page 215 - Internal Considerations
Page 216 - Risk Considerations
Page 217 - Base Salary
Page 218 - Parameters:
Page 219 - 2017 Annual Cash Incentives
Page 220 - CEO
Page 221 - Company-Level: Operational Measures
Page 222 - Individual Level
Page 223 - Equity-Based Compensation
Page 224 - Parameters
Page 225 - 2017 Long-Term Equity Incentives Annual Grant
Page 226 - PSU Calculation Methodology
Page 227 - N/A
Page 228 - 2017 Long-Term Incentive Award Values Annual Grant
Page 229 - N/A
Page 230 - Performance, Promotion and Other One-Time Grants
Page 231 - N/A
Page 232 - Appointment of Mr. Michael McClellan as CFO; Previous Appointment as Interim CFO
Page 233 - Appointment and Separation of Dr. Yitzhak Peterburg as Interim President and CEO
Page 234 - Separation of Dr. Michael Hayden
Page 235 - Clawback Policy
Page 236 - Anti-Hedging and Pledging Policies
Page 237 - Health and Welfare Benefits
Page 238 - Committee Report
Page 239 - ADDITIONAL COMPENSATION INFORMATION
Page 240 - Bonus
Page 241 - All Other Compensation
Page 242 - K re Schultz
Page 243 - Mark Sabag
Page 244 - Eyal Desheh
Page 245 - 2017 Pay Ratio
Page 246 - N/A
Page 247 - 2017 Grants of Plan-Based Awards
Page 248 - Performance Share Units (PSUs)
Page 249 - Sign-On Grants to Mr. Schultz of PSUs and RSUs
Page 250 - 2017 Outstanding Equity Awards at Fiscal Year-End
Page 251 - N/A
Page 252 - N/A
Page 253 - 2017 Option Exercises and Stock Vested
Page 254 - Supplemental Deferred Compensation Plan
Page 255 - 2017 Potential Payments Upon Termination or Change in Control
Page 256 - Michael McClellan
Page 257 - Dr. Carlo de Notaristefani
Page 258 - Mark Sabag
Page 259 - Dr. Yitzhak Peterburg
Page 260 - Dr. Michael Hayden
Page 261 - Accelerated/Continued Equity Vesting Upon Death or Disability
Page 262 - Non-Employee Director Compensation
Page 263 - 2017 Director Compensation
Page 264 - Compensation Committee Interlocks and Insider Participation
Page 265 - ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATT
Page 266 - Securities Authorized for Issuance under Equity Compensation Plans
Page 267 - ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
Page 268 - Director Independence
Page 269 - PART IV
Page 270 - N/A
Page 271 - N/A
Page 272 - N/A
Page 273 - N/A
Page 274 - N/A
Page 275 - N/A
Page 276 - N/A
Page 277 - ITEM 16. FORM 10-K SUMMARY
Page 278 - SIGNATURES
Page 279 - Name
Subdocument 2 - EX-3.2 - EX-3.2
Page 1 - Exhibit 3.2
Subdocument 3 - EX-3.3 - EX-3.3
Page 1 - Exhibit 3.3
Page 2 - Translated from the Hebrew
Page 3 - A. INTRODUCTION
Page 4 - Objectives and Purpose of the Company
Page 5 - Share Certificates
Page 6 - Bearer Share Warrants
Page 7 - Increase and Issue of the Registered Capital
Page 8 - Deliberations at General Meetings
Page 9 - N/A
Page 10 - Votes by the Shareholders
Page 11 - D. THE BOARD OF DIRECTORS
Page 12 - Remuneration of Directors
Page 13 - Powers and Duties of the Board of Directors
Page 14 - Committees of the Board of Directors
Page 15 - prima facie
Page 16 - Reserve Fund
Page 17 - G. AUDITING AND NOTICES
Page 18 - H. EXEMPTION, INSURANCE AND INDEMNIFICATION OF OFFICERS
Page 19 - I. MISCELLANEOUS
Page 20 - EXHIBIT A
Page 21 - Beneficial Owner
Page 22 - DTC
Page 23 - Fundamental Change Dividend Make-Whole Amount
Page 24 - Parity Shares
Page 25 - VWAP
Page 26 - Method of Payment of Dividends
Page 27 - provided, however
Page 28 - provided
Page 29 - Discount Rate
Page 30 - Conversion Procedures
Page 31 - Fundamental Change Conversion Date
Page 32 - Fractional ADSs
Page 33 - Issuance of Share Purchase Rights
Page 34 - Debt or Asset Distribution
Page 35 - Clause I Distribution
Page 36 - Fair Market Value in Excess of Ordinary Share Current Market Price
Page 37 - Fundamental Change Conversion Rate
Page 38 - Reorganization Events
Page 39 - Transfer Agent, Registrar, and Conversion and Dividend Disbursing Agent
Page 40 - Other Rights
Page 41 - Miscellaneous
Subdocument 4 - EX-10.6 - EX-10.6
Page 1 - Exhibit 10.6
Page 2 - Acquisition Closing Date
Page 3 - Consolidated Cash and Cash Equivalents
Page 4 - Transactions
Page 5 - provided
Page 6 - N/A
Page 7 - 5. Effectiveness.
Page 8 - 8. Severability.
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - Signature page to Fixed Rate Japanese Yen Credit Agreement Amendment Agreement
Page 13 - Signature page to Fixed Rate Japanese Yen Credit Agreement Amendment Agreement
Subdocument 5 - EX-10.7 - EX-10.7
Page 1 - Exhibit 10.7
Page 2 - Acquisition Financing Arrangement
Page 3 - Consolidated Cash and Cash Equivalents
Page 4 - Transactions
Page 5 - provided
Page 6 - N/A
Page 7 - 5. Effectiveness.
Page 8 - 12. Governing Law; Jurisdiction; Consent to Service of Process.
Page 9 - N/A
Page 10 - Signature page to Japanese Yen Credit Agreement Amendment Agreement
Page 11 - Signature page to Japanese Yen Credit Agreement Amendment Agreement
Page 12 - Signature page to Japanese Yen Credit Agreement Amendment Agreement
Subdocument 6 - EX-10.8 - EX-10.8
Page 1 - Exhibit 10.8
Page 2 - Bail-In Action
Page 3 - EEA Member Country
Page 4 - underlined
Page 5 - N/A
Page 6 - 13. Governing Law; Jurisdiction; Consent to Service of Process.
Page 7 - N/A
Page 8 - Signature page to Revolving Credit Agreement Amendment Agreement
Page 9 - Signature page to Revolving Credit Agreement Amendment Agreement
Page 10 - Signature page to Revolving Credit Agreement Amendment Agreement
Page 11 - Signature page to Revolving Credit Agreement Amendment Agreement
Page 12 - Signature page to Revolving Credit Agreement Amendment Agreement
Page 13 - Signature page to Revolving Credit Agreement Amendment Agreement
Subdocument 7 - EX-10.20 - EX-10.20
Page 1 - Exhibit 10.20
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - Exhibit E
Page 19 - inter alia
Page 20 - Non-Compete Payment
Page 21 - provided
Page 22 - N/A
Page 23 - provided
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - IN WITNESS WHEREOF
Page 28 - N/A
Page 29 - Exhibit A
Page 30 - Exhibit B
Page 31 - Exhibit C
Page 32 - No Violation of Law
Page 33 - Counterparts
Page 34 - Exhibit D
Page 35 - N/A
Page 36 - N/A
Page 37 - N/A
Page 38 - N/A
Page 39 - N/A
Page 40 - N/A
Page 41 - N/A
Page 42 - Schedule A
Page 43 - N/A
Page 44 - Schedule A
Page 45 - N/A
Page 46 - N/A
Page 47 - N/A
Page 48 - Exhibit E
Page 49 - Exhibit E
Page 50 - N/A
Page 51 - N/A
Page 52 - N/A
Page 53 - EMPLOYEE
Subdocument 8 - EX-10.21 - EX-10.21
Page 1 - Exhibit 10.21
Page 2 - N/A
Page 3 - CPI
Page 4 - Incentive Bonus
Page 5 - Employee Benefits
Page 6 - Insurance Arrangement
Page 7 - N/A
Page 8 - N/A
Page 9 - Study Fund
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - Annex C
Page 17 - inter alia
Page 18 - provided
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - IN WITNESS WHEREOF
Page 24 - Annex A
Page 25 - No Violation of Law
Page 26 - N/A
Page 27 - Annex B
Page 28 - Annex C
Page 29 - Annex C
Page 30 - N/A
Page 31 - N/A
Page 32 - N/A
Subdocument 9 - EX-10.22 - EX-10.22
Page 1 - Exhibit 10.22
Page 2 - N/A
Page 3 - Annex
Page 4 - N/A
Page 5 - Remunerations
Page 6 - Severance Pay
Page 7 - (Keren Hiskalmuo
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - Annex E
Page 16 - inter alia,
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - IN WITNESS WHEREOF
Subdocument 10 - EX-10.23 - EX-10.23
Page 1 - Exhibit 10.23
Page 2 - Translation from the Hebrew
Page 3 - Translation from the Hebrew
Page 4 - Translation from the Hebrew
Page 5 - Translation from the Hebrew
Page 6 - Translation from the Hebrew
Page 7 - Translation from the Hebrew
Page 8 - Translation from the Hebrew
Page 9 - Translation from the Hebrew
Page 10 - Translation from the Hebrew
Page 11 - Translation from the Hebrew
Page 12 - Translation from the Hebrew
Page 13 - Translation from the Hebrew
Page 14 - Translation from the Hebrew
Page 15 - Translation from the Hebrew
Subdocument 11 - EX-10.24 - EX-10.24
Page 1 - Exhibit 10.24
Subdocument 12 - EX-10.25 - EX-10.25
Page 1 - Exhibit 10.25
Page 2 - Translation from the Hebrew
Subdocument 13 - EX-10.26 - EX-10.26
Page 1 - Exhibit 10.26
Page 2 - Translation from the Hebrew
Page 3 - Translation from the Hebrew
Page 4 - Translation from the Hebrew
Page 5 - Translation from the Hebrew
Page 6 - Translation from the Hebrew
Page 7 - Translation from the Hebrew
Page 8 - Translation from the Hebrew
Page 9 - Translation from the Hebrew
Subdocument 14 - EX-10.27 - EX-10.27
Page 1 - Exhibit 10.27
Page 2 - provided
Page 3 - Equity Plan
Page 4 - Termination of Employment
Page 5 - Termination by Teva USA for Cause
Page 6 - Termination by the Executive for Good Reason
Page 7 - Notice Period
Page 8 - Compliance with Covenants
Page 9 - DTSA Disclosure
Page 10 - Covenant Not to Compete
Page 11 - Injunctive Relief
Page 12 - Insurance
Page 13 - Clawback
Page 14 - provided
Page 15 - Signature Page to Employment Agreement
Page 16 - EXHIBIT A
Page 17 - EEOC
Page 18 - N/A
Subdocument 15 - EX-10.28 - EX-10.28
Page 1 - Exhibit 10.28
Page 2 - Notice
Subdocument 16 - EX-10.29 - EX-10.29
Page 1 - Exhibit 10.29
Page 2 - Private Confidential
Subdocument 17 - EX-10.30 - EX-10.30
Page 1 - Exhibit 10.30
Page 2 - COMPENSATION
Page 3 - Insurance
Page 4 - INTERCULTURAL ORIENTATION
Page 5 - PENSION SOCIAL SECURITY
Page 6 - INVOLUNTARY TERMINATION OF EMPLOYMENT
Page 7 - N/A
Subdocument 18 - EX-10.31 - EX-10.31
Page 1 - Exhibit 10.31
Page 2 - provided, however,
Page 3 - Company Car
Page 4 - Disability
Page 5 - provided,
Page 6 - Good Reason
Page 7 - Change of Control.
Page 8 - provided, however,
Page 9 - Inventions
Page 10 - Blue Pencil.
Page 11 - Clawback.
Page 12 - No Mitigation.
Page 13 - N/A
Page 14 - Exhibit A
Page 15 - EEOC
Subdocument 19 - EX-10.32 - EX-10.32
Page 1 - Exhibit 10.32
Page 2 - provided
Page 3 - Equity Awards
Page 4 - Termination of Employment
Page 5 - Termination by Teva USA for Cause
Page 6 - multiplied by
Page 7 - Good Reason
Page 8 - Compliance with Covenants
Page 9 - Executive
Page 10 - Covenant Not to Interfere
Page 11 - Cooperation.
Page 12 - provided
Page 13 - Governing Law; Severability
Page 14 - Counterparts
Page 15 - N/A
Page 16 - EXHIBIT A
Page 17 - EEOC
Page 18 - ab
Page 19 - EXHIBIT B
Page 20 - Exhibit C
Page 21 - mens rea
Page 22 - provided
Page 23 - provided
Page 24 - N/A
Page 25 - Independent Counsel
Page 26 - provided
Page 27 - N/A
Page 28 - Schedule A
Page 29 - Accepted and agreed
Page 30 - Schedule A
Page 31 - N/A
Page 32 - N/A
Page 33 - N/A
Subdocument 20 - EX-10.33 - EX-10.33
Page 1 - Exhibit 10.33
Subdocument 21 - EX-10.34 - EX-10.34
Page 1 - Exhibit 10.34
Page 2 - Other Terms
Subdocument 22 - EX-10.35 - EX-10.35
Page 1 - Exhibit 10.35
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - Counterparts
Subdocument 23 - EX-10.36 - EX-10.36
Page 1 - Exhibit 10.36
Page 2 - Teva Pharmacedutical Industires Ltd. Human Resources.
Subdocument 24 - EX-10.37 - EX-10.37
Page 1 - Exhibit 10.37
Page 2 - Term
Page 3 - Incentive Bonus
Page 4 - provided
Page 5 - provided
Page 6 - Insurance Arrangement
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - inter alia,
Page 11 - provided, however
Page 12 - IN WITNESS WHEREOF
Subdocument 25 - EX-10.38 - EX-10.38
Page 1 - Exhibit 10.38
Subdocument 26 - EX-10.39 - EX-10.39
Page 1 - Exhibit 10.39
Page 2 - Execution Copy
Page 3 - Execution Copy
Page 4 - Execution Copy
Page 5 - Execution Copy
Page 6 - Execution Copy
Page 7 - Execution Copy
Page 8 - Execution Copy
Subdocument 27 - EX-10.40 - EX-10.40
Page 1 - Exhibit 10.40
Page 2 - IN WITNESS WHEREOF,
Subdocument 28 - EX-10.41 - EX-10.41
Page 1 - Exhibit 10.41
Page 2 - N/A
Subdocument 29 - EX-10.42 - EX-10.42
Page 1 - Exhibit 10.42
Page 2 - N/A
Page 3 - N/A
Subdocument 30 - EX-10.43 - EX-10.43
Page 1 - Exhibit 10.43
Page 2 - HAVE AGREED AS FOLLOWS:
Page 3 - Final settlement of accounts
Page 4 - Miscellaneous
Page 5 - board member
Subdocument 31 - EX-10.44 - EX-10.44
Page 1 - Exhibit 10.44
Page 2 - EXECUTION COPY
Page 3 - EXECUTION COPY
Page 4 - EXECUTION COPY
Page 5 - EXECUTION COPY
Page 6 - EXECUTION COPY
Page 7 - EXECUTION COPY
Page 8 - EXECUTION COPY
Page 9 - EXECUTION COPY
Page 10 - EXECUTION COPY
Page 11 - EXECUTION COPY
Page 12 - EXECUTION COPY
Page 13 - EXECUTION COPY
Page 14 - EXECUTION COPY
Page 15 - EXECUTION COPY
Page 16 - EXECUTION COPY
Page 17 - EXECUTION COPY
Page 18 - EXECUTION COPY
Page 19 - EXECUTION COPY
Page 20 - EXECUTION COPY
Page 21 - EXECUTION COPY
Page 22 - EXECUTION COPY
Page 23 - EXECUTION COPY
Page 24 - EXECUTION COPY
Page 25 - EXECUTION COPY
Page 26 - EXECUTION COPY
Page 27 - EXECUTION COPY
Page 28 - EXECUTION COPY
Page 29 - EXECUTION COPY
Page 30 - EXECUTION COPY
Page 31 - EXECUTION COPY
Page 32 - EXECUTION COPY
Page 33 - EXECUTION COPY
Page 34 - EXECUTION COPY
Page 35 - EXECUTION COPY
Page 36 - EXECUTION COPY
Page 37 - EXECUTION COPY
Page 38 - EXECUTION COPY
Page 39 - EXECUTION COPY
Page 40 - EXECUTION COPY
Page 41 - EXECUTION COPY
Page 42 - EXECUTION COPY
Page 43 - EXECUTION COPY
Page 44 - EXECUTION COPY
Page 45 - EXECUTION COPY
Page 46 - EXECUTION COPY
Page 47 - EXECUTION COPY
Page 48 - EXECUTION COPY
Subdocument 32 - EX-10.45 - EX-10.45
Page 1 - Exhibit 10.45
Page 2 - N/A
Subdocument 33 - EX-10.46 - EX-10.46
Page 1 - Exhibit 10.46
Page 2 - Notes
Subdocument 34 - EX-10.49 - EX-10.49
Page 1 - Exhibit 10.49
Page 2 - ARTICLE 1
Page 3 - Code
Page 4 - Deemed Investment Options
Page 5 - Plan Distribution Date
Page 6 - Teva Pharmaceuticals USA, Inc.
Page 7 - Timing of Compensation Deferral Elections
Page 8 - Supplemental Contributions
Page 9 - ARTICLE 5
Page 10 - Valuation of Accounts
Page 11 - Benefits Upon Separation from Service Prior to Retirement
Page 12 - Retirement Distribution Account
Page 13 - Survivor Benefits Under Flexible Distribution Option
Page 14 - ARTICLE 10
Page 15 - Limited Cash-Outs
Page 16 - Delay of Payments
Page 17 - Payments Upon Termination of Plan
Page 18 - ARTICLE 11
Page 19 - Request for Review
Page 20 - Limitation of Participant s Right
Page 21 - Unfunded Status of Plan
Page 22 - Payments on Behalf of Persons
Subdocument 35 - EX-10.50 - EX-10.50
Page 1 - Exhibit 10.50
Page 2 - TABLE OF CONTENTS
Page 3 - TABLE OF CONTENTS
Page 4 - THE TEVA PHARMACEUTICALS USA, INC. DEFINED CONTRIBUTION
Page 5 - Beneficiary
Page 6 - Company
Page 7 - Election Form
Page 8 - Service Credit
Page 9 - ARTICLE III
Page 10 - ARTICLE IV
Page 11 - 4.4. Statements
Page 12 - ARTICLE V
Page 13 - 5.2. Forfeiture of Benefits
Page 14 - N/A
Page 15 - ARTICLE VI
Page 16 - Installment Payment Amounts
Page 17 - Violation of Applicable Law
Page 18 - 6.4. Incapacity of Recipient
Page 19 - 7.3. Trust
Page 20 - provided
Page 21 - N/A
Page 22 - Disability Claims
Page 23 - N/A
Page 24 - Exhaustion of Remedies
Page 25 - ARTICLE XI
Page 26 - 11.6. Binding upon Successors
Page 27 - 11.12. Governing Law
Page 28 - APPENDIX A
Subdocument 36 - EX-10.51 - EX-10.51
Page 1 - Exhibit 10.51
Page 2 - expenses
Page 3 - provided
Page 4 - provided
Page 5 - N/A
Page 6 - Independent Counsel
Page 7 - N/A
Page 8 - Schedule A
Page 9 - [signature page of the Indemnification and Release Agreement]
Page 10 - Schedule A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Subdocument 37 - EX-10.52 - EX-10.52
Page 1 - Exhibit 10.52
Page 2 - N/A
Page 3 - N/A
Subdocument 38 - EX-10.53 - EX-10.53
Page 1 - Exhibit 10.53
Page 2 - N/A
Page 3 - Counterparts; Electronic Signature
Subdocument 39 - EX-10.54 - EX-10.54
Page 1 - Exhibit 10.54
Page 2 - N/A
Page 3 - N/A
Page 4 - Committee
Page 5 - Taxes
Page 6 - N/A
Subdocument 40 - EX-10.55 - EX-10.55
Page 1 - Exhibit 10.55
Page 2 - N/A
Page 3 - N/A
Subdocument 41 - EX-10.56 - EX-10.56
Page 1 - Exhibit 10.56
Page 2 - Taxes
Page 3 - N/A
Subdocument 42 - EX-10.57 - EX-10.57
Page 1 - Exhibit 10.57
Page 2 - N/A
Page 3 - N/A
Subdocument 43 - EX-10.58 - EX-10.58
Page 1 - Exhibit 10.58
Page 2 - N/A
Page 3 - N/A
Subdocument 44 - EX-10.59 - EX-10.59
Page 1 - Exhibit 10.59
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Subdocument 45 - EX-10.60 - EX-10.60
Page 1 - Exhibit 10.60
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - Grant of Options
Page 7 - Vesting
Page 8 - Clawback/Recoupment Policy
Subdocument 46 - EX-10.61 - EX-10.61
Page 1 - Exhibit 10.61
Page 2 - N/A
Page 3 - N/A
Page 4 - Grant of Options
Page 5 - Taxes
Subdocument 47 - EX-10.62 - EX-10.62
Page 1 - Exhibit 10.62
Page 2 - N/A
Page 3 - Grant of Options
Page 4 - Determination of the Earned PSUs
Page 5 - Withholding
Page 6 - Binding Effect
Subdocument 48 - EX-10.63 - EX-10.63
Page 1 - Exhibit 10.63
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - Grant of Options
Page 7 - Vesting
Page 8 - Clawback/Recoupment Policy
Subdocument 49 - EX-10.64 - EX-10.64
Page 1 - Exhibit 10.64
Page 2 - Threshold:
Subdocument 50 - EX-10.65 - EX-10.65
Page 1 - Exhibit 10.65
Page 2 - Taxes
Page 3 - N/A
Subdocument 51 - EX-10.66 - EX-10.66
Page 1 - Exhibit 10.66
Page 2 - WHEREAS
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - [SIGNATURE PAGES FOLLOW]
Page 12 - N/A
Subdocument 52 - EX-21 - EX-21
Page 1 - Exhibit 21
Subdocument 53 - EX-23 - EX-23
Page 1 - Exhibit 23
Subdocument 54 - EX-31.1 - EX-31.1
Page 1 - Exhibit 31.1
Subdocument 55 - EX-31.2 - EX-31.2
Page 1 - Exhibit 31.2
Subdocument 56 - EX-32 - EX-32
Page 1 - Exhibit 32
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer